


Anti-KRAS Recombinant Antibody Products

Anti-KRAS Products
- Recombinant Mouse Anti-Human KRAS Antibody (MOB-1757MZ)
-
- Species Reactivity: Human
- Type: Mouse antibody
- Application: FC, IHC-P, WB
-
- Derivation: Mouse
- Species Reactivity: Human
- Type: Mouse IgG2b, κ
- Application: WB, ELISA, FC, ICC, IF
- Human Anti-KRAS Recombinant Antibody (HPAB-N0159-YC) (HPAB-N0159-YC)
-
- Species Reactivity: Human
- Type: Human IgG
- Application: ELISA
- Rabbit Anti-KRAS Polyclonal Antibody (MRO-2154-CN) (MRO-2154-CN)
-
- Species Reactivity: Human, Mouse, Rat
- Type: Rabbit IgG
- Application: WB, IF, IHC, FC
- Human Anti-KRAS Recombinant Antibody; scFv Fragment (HPAB-N0159-YC-S(P)) (HPAB-N0159-YC-S(P))
-
- Species Reactivity: Human
- Type: Human scFv
- Application: ELISA
- Human Anti-KRAS Recombinant Antibody; Fab Fragment (HPAB-N0159-YC-F(E)) (HPAB-N0159-YC-F(E))
-
- Species Reactivity: Human
- Type: Human Fab
- Application: ELISA
- Recombinant Camelid Anti-KRAS Single Domain Antibody (HPAB-0346-YC-VHH) (HPAB-0346-YC-VHH)
-
- Derivation: Ribosome display
- Species Reactivity: Human
- Type: Camel VHH
- Application: Cyto, Block, ELISA
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: IHC
- Anti-KRAS Immunohistochemistry Kit (VS-0525-XY3825)
-
- Species Reactivity: Human
- Target: KRAS
- Application: IHC
-
- Derivation: Phage display library screening
- Species Reactivity: Human
- Type: IgG
- Application: WB, ICC, IP
- Rabbit Anti-KRAS Recombinant Antibody (clone AFY0002) (MOR-0031-FY)
-
- Species Reactivity: Human
- Type: Rabbit IgG
- Application: IHC-P, WB
-
- Antibody Host: Mouse
- Antibody Reactivity: Human
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs offers a premier selection of innovative recombinant antibodies targeting KRAS, playing a vital role in advancing biomedical science. Through the use of cutting-edge technology platforms, we ensure that each product adheres to rigorous standards of quality, consistency, and performance. Our extensive catalog reflects our unwavering commitment to driving scientific progress, with each antibody solution engineered for outstanding reliability and value. In addition to delivering top-tier reagents, we provide expert technical support to guide researchers throughout their experimental journey. Partnering with Creative Biolabs means accessing not only advanced tools but also a trusted ally committed to the success of your research.
KRAS: A Pivotal Target in Cancer Progression and Precision Oncology
KRAS is a well-established oncogene that plays a critical role in the development and progression of various cancers, including pancreatic, colorectal, and non-small cell lung cancer. As part of the RAS family of GTPases, KRAS regulates essential cellular functions such as proliferation, differentiation, and survival. Mutations in the KRAS gene often lead to uncontrolled cell signaling, contributing to tumor growth and resistance to therapy. Due to its high mutation frequency and central role in oncogenic pathways, KRAS has become a major focus in cancer research and drug development. Targeting KRAS-driven signaling offers promising therapeutic potential, particularly in tumors previously considered undruggable.
Alternative Names
Complement NS; NS3; CFC2; RALD; K-Ras; KRAS1; KRAS2; RASK2; KI-RAS; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; c-Ki-ras2
Background
This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.
Anti-KRAS rAb Products
We are dedicated to accelerating scientific advancement by providing premium anti-KRAS recombinant antibodies, combining exceptional performance, cost-effectiveness, and reliable technical guidance. Our goal is to empower researchers with the tools and support they need to drive meaningful discoveries.
Cat. No. | Product Name | Target Species | Host Species | Applications |
HPAB-N0159-YC | Human Anti-KRAS Recombinant Antibody (HPAB-N0159-YC) | Human | Human | ELISA |
MOB-1225z | Mouse Anti-KRAS Recombinant Antibody (clone 23A6) | Human | Mouse | WB; ELISA; FC; ICC; IF |
MOB-1757MZ | Recombinant Mouse Anti-Human KRAS Antibody | Human | Mouse | FC; IHC-P; WB |
MOR-0031-FY | Rabbit Anti-KRAS Recombinant Antibody (clone AFY0002) | Human | Rabbit | IHC-P; WB |
Customer Reviews

Mouse Anti-KRAS Recombinant Antibody (clone 23A6) (CAT#: MOB-1225z)

Recombinant Mouse Anti-Human KRAS Antibody (CAT#: MOB-1757MZ)
rAb Production
With years of experience in developing and optimizing recombinant antibodies, we are able to offer high-quality products with consistent performance. Our efficient processes and commitment to excellence ensure timely delivery and dependable service tailored to researchers' needs.
Featured Anti-KRAS Recombinant Antibody Production Platforms
Fig.1 Milligram-scale recombinant antibody production.
Fig.2 Gram-scale recombinant antibody production.
rAb Modalities
Creative Biolabs is committed to providing researchers with a diverse selection of cutting-edge recombinant antibodies in multiple formats. With extensive expertise in recombinant antibody technologies, we employ a variety of advanced engineering techniques. Additionally, we offer exceptional custom engineering services designed to meet the unique requirements of your research.
Fig.3 Full Length Anti-KRAS Recombinant Antibody Production and Modalities.
Drug Information Targeting KRAS
Table 1. Therapeutic approaches targeting KRAS in clinical development.
Research phase | Company | Classification | Indications | Details |
Phase II | Gritstone bio | Biologics | Cancer | It is an optimized neoantigen immunotherapy targeting mutated KRAS, developed by Gritstone bio and currently under phase II evaluation for KRAS-mutant non-small cell lung and colorectal cancers. |
Phase II | Silenseed | Biologics | Cancer | It is a biodegradable RNA-based therapy targeting KRASG12D, developed by Silenseed for unresectable pancreatic cancer and currently in phase II trials, with orphan drug status granted by the FDA in 2015. |
Phase I/II | Mirati Therapeutics | Small Molecules | Cancer; Solid tumor | It is an oral small-molecule SOS1 inhibitor developed by Mirati Therapeutics, now part of Bristol-Myers Squibb, for treating KRAS- or MAPK-driven solid tumors, currently in early clinical development. |
Phase I/II | Mirati Therapeutics | Small Molecules | Cancer; Solid tumor | It is an oral small-molecule inhibitor of KRASG12D developed by Mirati Therapeutics for advanced solid tumors, including NSCLC, CRC, and pancreatic cancer, with selectivity demonstrated in preclinical studies. |
Phase I/II | Elicio Therapeutics | Drug Conjugates | Cancer; Solid tumor | It is a cancer vaccine developed by Elicio Therapeutics for KRAS-driven solid tumors in patients with minimal residual disease after surgical resection, currently in early clinical development. |
Phase I | Chugai Pharmaceutical | Peptides | Cancer; Solid tumor | It is an oral RAS inhibitor developed by Chugai for the treatment of locally advanced or metastatic solid tumors, currently in early clinical development. |
Phase I | Jiangsu Hengrui | Others | Cancer; Solid tumor | It is a KRAS G12D-targeting therapy developed by Jiangsu Hengrui, currently being assessed in early clinical trials for advanced solid tumors. |
Phase I | Revolution Medicines | Small Molecules | Cancer; Solid tumor | It is a covalent and mutant-selective KRASG12D(ON) inhibitor developed by Revolution Medicines, currently in phase I trials for the treatment of KRASG12D-mutant solid tumors. |
Phase I | Astellas Pharma | Others | Cancer; Solid tumor | It is a small-molecule KRAS G12D degrader developed by Astellas Pharma, currently in early clinical trials for advanced solid tumors, with FDA fast track designation granted in 2023 for pancreatic, colorectal, and non-small cell lung cancers. |
Phase I | RasCal Therapeutics | Others | Cancer; Solid tumor | It is an oral small-molecule KRAS inhibitor targeting both wild-type and mutant forms, developed by RasCal Therapeutics for advanced solid tumors and currently in early clinical development. |
If you need further details about the KRAS target, don't hesitate to contact us by phone or email. Our expert team is happy to help with any questions or issues you may encounter in your research, providing the support you need for a successful outcome.